Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies - Episode 4
Case Presentation 1: PIK3CA Mutation With ESR1 Mutations
Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, present a patient case involving a 54-year-old postmenopausal woman diagnosed with a 2.1cm estrogen receptor positive (ER+), HER2 negative breast cancer, and discuss the clinical implications and management strategies for this specific patient scenario.
Video Player is loading.
- How does this truncal vs acquired distinction impact treatment strategies for ESR1 mutation-positive disease?
- What criteria are used to classify ESR1 mutations as truncal vs acquired?